Matthew Baker

Title: Matthew Baker - Innovator in Modified Bouganin Proteins

Introduction

Matthew Baker is a notable inventor based in Great Britain. He has made significant contributions to the field of biotechnology, particularly in the development of modified bouganin proteins. His work focuses on creating proteins with enhanced biological activity and reduced side effects, particularly in relation to human T cell activation.

Latest Patents

Matthew Baker holds a patent titled "Modified Bouganin Proteins, Cytotoxins And Methods And Uses Thereof." This patent describes modified forms of bouganin protein that exhibit biological activity while having a reduced propensity to activate human T cells compared to the non-modified version. The patent also includes T-cell epitope peptides of bouganin, which similarly have a reduced tendency to activate human T cells. Additionally, it covers cytotoxins that bind to cancer cells and are linked to modified bouganin proteins. The methods outlined in the patent aim to inhibit or destroy mammalian cancer cells using these cytotoxins, along with pharmaceutical compositions for treating human cancer.

Career Highlights

Throughout his career, Matthew Baker has worked on innovative solutions in the biotechnology sector. His research has focused on enhancing the efficacy of cancer treatments through the use of modified proteins. Despite having no patents listed under his name, his contributions to the field are noteworthy.

Collaborations

Matthew Baker has collaborated with notable professionals in his field, including Francis J. Carr and Koen Hellendoorn. These collaborations have likely enriched his research and development efforts, leading to advancements in the applications of bouganin proteins.

Conclusion

Matthew Baker is an influential figure in the realm of biotechnology, particularly in the development of modified bouganin proteins for cancer treatment. His innovative work continues to pave the way for new therapeutic approaches in the fight against cancer.